請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23275
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 高純琇(Churn-Shiouh Gau) | |
dc.contributor.author | Shih-Chin Chen | en |
dc.contributor.author | 陳世芹 | zh_TW |
dc.date.accessioned | 2021-06-08T04:51:08Z | - |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-15 | |
dc.identifier.citation | 1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.
2. 98年度衛生統計系列之死因統計. 中華民國行政院衛生署, 2009. (Accessed 11.9, 2010, at http://www.doh.gov.tw/CHT2006/DM/DM2_2_p02.aspx?class_no=440&now_fod_list_no=11468&level_no=1&doc_no=77184.) 3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. 4. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71. 5. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98:1597-603. 6. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9. 7. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98:2126-32. 8. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-22. 9. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33. 10. Steinhubl SR, Berger PB, Mann JT, 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. 11. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17. 12. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8. 13. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68. 14. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. 15. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-6. 16. Grines CL, Bonow RO, Casey DE, Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-8. 17. Kushner FG, Hand M, Smith SC, Jr., et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-306. 18. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57:e215-367. 19. Sarah A. Spinler SdD. Acute Coronary Syndrome. In: al. JTDe, ed. Pharmacotherapy: a Pathophysiological Approach. 7 ed. New York: McGraw-Hill; 2008:249-73. 20. Toby C. Trujillo PEN. Ischemic heart disease: Anginal syndromes. In: Applied Therapeutics: The clinical use of drugs. 9 ed:1-31. 21. 98年度全民健康保險醫療統計年報. 中華民國行政院衛生署, 2009. (Accessed 11.7, 2010, at http://www.doh.gov.tw/CHT2006/DM/DM2_2_p02.aspx?class_no=440&now_fod_list_no=11468&level_no=1&doc_no=77184.) 22. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e426-579. 23. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Can J Cardiol 2004;20:977-1025. 24. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51:210-47. 25. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106. 26. Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005;46:1242-8. 27. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:671-719. 28. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343:311-22. 29. Lewis HD, Jr., Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403. 30. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-75. 31. Duerschmied D, Bode C, Moser M. Clopidogrel in acute coronary syndrome: implications of recent study findings. Expert Rev Cardiovasc Ther 2010;8:1215-29. 32. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39. 33. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89. 34. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21. 35. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157. 36. King SB, 3rd, Smith SC, Jr., Hirshfeld JW, Jr., et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261-95. 37. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. 38. Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:776S-814S. 39. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111:2257-73. 40. Abbott JD, Voss MR, Nakamura M, et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007;50:2029-36. 41. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006;92:641-9. 42. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23. 43. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-402. 44. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-409. 45. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71. 46. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-41. 47. Castellot JJ, Jr., Addonizio ML, Rosenberg R, Karnovsky MJ. Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol 1981;90:372-9. 48. Awata M, Kotani J, Uematsu M, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 2007;116:910-6. 49. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-6. 50. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11. 51. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202. 52. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9. 53. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9. 54. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61. 55. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48. 56. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21. 57. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91. 58. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54. 59. Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009;30:2714-21. 60. Park DW, Yun SC, Lee SW, et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2008;1:494-503. 61. Stone GW, Ellis SG, Colombo A, et al. Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data). Am J Cardiol 2008;102:1017-22. 62. Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009;119:987-95. 63. Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 2008;51:2220-7. 64. Butler MJ, Eccleston D, Clark DJ, et al. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. Am Heart J 2009;157:899-907. 65. Rossini R, Capodanno D, Lettieri C, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011;107:186-94. 66. Banerjee S, Varghese C, Samuel J, et al. Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol 2008;102:1159-62. 67. Harjai KJ, Shenoy C, Orshaw P, Boura J. Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. Heart 2009;95:1579-86. 68. Wiederkehr D, Ogbonnaya A, Casciano R, Makenbaeva D, Mozaffari E, Corbelli J. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. Curr Med Res Opin 2009;25:2327-34. 69. Ernst FR, Johnston S, Curkendall S, Mozaffari E, Stemkowski S. Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: Results from two distinct patient populations. Am J Health Syst Pharm 2011;68:1015-24. 70. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9. 71. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-8. 72. Patel JH, Stoner JA, Owora A, Mathew ST, Thadani U. Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. Am J Cardiol 2009;103:1687-93. 73. Gao G, Zheng Z, Pi Y, Lu B, Lu J, Hu S. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol 2010;56:1639-43. 74. Kulik A, Le May MR, Voisine P, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation 2010;122:2680-7. 75. Disparities in screening for and awareness of high blood cholesterol--United States, 1999-2002. MMWR Morb Mortal Wkly Rep 2005;54:117-9. 76. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47. 77. 96年度台灣菸害防制年報. 2007. (Accessed 6/15, 2011, at 78. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-88. 79. Talbert RL, ed. Hyperlipidemia. 7 ed. New York: McGraw-Hill; 2008. 80. Lisa A. Kroon MA, Betsy A. Carlisle, ed. Diabetes Mellitus. 9 ed. 81. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009;119:3198-206. 82. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010;55:543-54. 83. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-8. 84. Dawkins KD, Chevalier B, Suttorp MJ, et al. Effectiveness of 'direct' stenting without balloon predilatation (from the Multilink Tetra Randomised European Direct Stent Study [TRENDS]). Am J Cardiol 2006;97:316-21. 85. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6. 86. Taggart DP, Kaul S, Boden WE, et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol 2008;51:885-92. 87. Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS. Identifying the 'optimal' duration of dual antiplatelet therapy after drug-eluting stent revascularization. JACC Cardiovasc Interv 2009;2:1279-85. 88. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the 'Emperor's New Clothes' revisited. Eur Heart J 2004;25:720-2. 89. Ho PM, Fihn SD, Wang L, et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J 2007;154:846-51. 90. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-41, 41 e1. 91. Byrne RA, Schulz S, Mehilli J, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 2009;157:620-4 e2. 92. Valgimigli M, Campo G, Percoco G, et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Am Heart J 2010;160:804-11. 93. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-82. 94. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation 2007;115:2352-7. 95. Yoseph Rozenman DS, Mervyn S. Gotsman. Restenosis and Progression of Coronary Disease after Balloon Angioplasty in Patients with Diabetes Mellitus. Clinical Cardiology 2000;23:890-4. 96. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006;29:1955-62. 97. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 2006;97:1478-81. 98. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297:1992-2000. 99. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006;27:1657-63. 100. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165:978-84. 101. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23275 | - |
dc.description.abstract | 研究背景: 臨床試驗已證實雙重抗血小板藥物(aspirin併用clopidogrel)預防急性冠心症病人再發生心血管事件的效用,目前美國心臟學會治療指引建議急性冠心症病人應併用aspirin與clopidogrel至少12個月,反觀我國健保目前僅給付clopidogrel併用aspirin最長達9個月,可知兩者之間並不一致。此外,近年來許多文獻顯示塗藥支架可能增加晚期支架栓塞的風險,而病人若提前停用雙重抗血小板藥物亦會顯著增加支架栓塞發生率,故對於塗藥支架病人而言,最適當的雙重抗血小板藥物療程應維持多久,目前仍不甚確定,而有限的資料尚未能證實療程超過一年是否具有臨床效益。
研究目的: (1)比較台灣健保給付 (九個月) 與國際學會治療指引建議的併用一年,療程長短對於病人預後再發生心血管事件的影響。(2)探討植入塗藥支架病人延長併用clopidogrel及aspirin超過一年的必要性。 研究方法: 本研究為一回溯性世代研究,以北部某醫學中心醫令系統資料庫及紙本病歷為研究材料,篩選出2007年7月至2009年6月新住院診斷為急性冠心症(ACS)且接受經皮冠狀動脈介入術之clopidogrel使用病人,第一部分為處方型態分析:分析研究族群clopidogrel與aspirin的開方情形及療程時間。第二部分為描述性分析及存活分析:將同一群研究族群依三個時間點進行分析,而這三個時間點分別是病人首次ACS出院後的九個月、十二個月及十五個月,研究終點定義為「再次ACS住院事件」。研究分為三部分—將研究族群依九個月內、十二個月內及十五個月內使用clopidogrel情形分別分為「提前停藥組」及「持續用藥組」,首先分析兩組間背景資料的差異,其次利用time-dependent Cox’s proportional hazard model進行存活分析,探討clopidogrel療程對於研究終點的影響,並篩選植入塗藥支架病人進行次群體分析。 研究結果: 研究族群共975人,平均追蹤時間為27個月。 (一)處方型態分析結果:研究族群一年內使用clopidogrel平均天數為259.38±114.13天,而療程超過9個月的病人占57.4 %,此群病人使用之中位數天數為364天,有48.6 %病人曾自費使用。 (二)描述性分析:影響病人使用≥12個月clopidogrel療程的因素包含—病人初次入院為心肌梗塞表現、多條血管阻塞、植入的支架為塗藥支架、支架放置在RCA、支架總長度較長、支架徑寬較小或病人患有高血壓;而影響病人使用≥15個月clopidogrel療程的因素,則包含—病人年紀較大、屬於多條血管阻塞、阻塞位置位於ostium、植入的支架為塗藥支架、支架放置在left main coronary artery (LM)、植入兩支以上的支架或支架總長度較長。 (三)存活分析結果: a)九個月療程分析,首次ACS出院(index date)九個月後仍存在研究中的有744位病人,將其依clopidogrel用藥情形分為「9個月前提前停藥組」292人 及「9個月持續用藥組」452人,校正可能的干擾因子後,「9個月持續用藥組」的adjusted hazard ratio (HR)為0.69 (95 % CI=0.48-1.00, p=0.05),顯示clopidogrel療程維持至少9個月能降低病人再次ACS住院的風險。 b)十二個月療程分析,index date後12個月仍存在研究中的病人有699人,「12個月前提前停藥組」有382人,「12個月持續用藥組」有317人,「12個月持續用藥組」的adjusted hazard ratio (HR)為0.59 (95 % CI=0.36-0.95, p=0.03),由此可知維持療程至少12個月能顯著降低病人再次ACS住院風險。 c)十五個月療程分析,index date後15個月仍存在研究中共653人,「15個月前提前停藥組」有489人,「15個月持續用藥組」則有164人,存活分析結果顯示「15個月持續用藥組」的adjusted HR為0.57 (95 % CI=0.29-1.13,p=0.11),並未發現使用clopidogrel大於等於15個月有顯著之效益。 d)塗藥支架次群體分析,「使用clopidogrel大於等於9個月」並未得到顯著意義,adjusted hazard ratio為0.68 (95 % CI=0.44-1.06,p=0.09),但「使用clopidogrel大於等於12個月」則達到統計上的顯著,adjusted hazard ratio為0.52 (95% CI=0.29-0.92,p=0.02),顯示植入塗藥支架病人若僅服用clopidogrel至9個月並未能顯著降低再次ACS住院事件風險,必須要服用至少12個月才有顯著效益。而「使用clopidogrel大於等於15個月」則並未看到顯著效益,adjusted HR為0.76 (95 % CI=0.37-1.56,p=0.45)。 結論: 急性冠心症病人應於術後維持至少12個月的clopidogrel療程,尤其對於塗藥支架的病人而言,完成12個月療程的重要性更為顯著。相較之下,健保給付的9個月療程稍顯不足,故在此建議健保放寬給付clopidogrel併用aspirin達12個月。 | zh_TW |
dc.description.abstract | Background: Results from randomized studies have confirmed the efficacy of dual antiplatelet therapy of aspirin and clopidogrel in the reduction of the incidence of recurrent cardiovascular events. Current ACC/AHA guidelines recommend that in addition to aspirin, clopidogrel should be continued for 12 months in patients with acute coronary syndrome (ACS). However, the reimbursement program of NHI only pays for the cost on clopidogrel in addition to aspirin up to 9 months, 3 months shorter than that suggested by the ACC/AHA guideline. Moreover, there have been numerous reports of late stent thrombosis in drug-eluting stent-treated patients, particularly after premature discontinuation of dual antiplatelet therapy. The optimal duration of dual antiplatelet therapy for patients receiving drug-eluting stents (DES) is not entirely clear so far. The benefit of extended therapy beyond 1 year is still uncertain.
Objectives: (1) To investigate the effect of dual antiplatelet therapy duration on the long-term clinical outcomes of ACS patients. (2) To evaluate the necessity of the use of dual antiplatelet therapy for more than 12 months in DES-treated patients. Methods: A retrospective cohort study was conducted using the computerized medical system and patient records in a medical center. We identified new ACS hospitalization patients receiving percutaneous coronary intervention and using clopidogrel after discharge during 2007/7 to 2009/6. Prescription analysis. We analysed the prescriptions patterns and mean duration of clopidogrel and aspirin use in the study population. Descriptive analysis. According to the duration of clopidogrel use within certain timeframes (9 months, 12 months or 15 months) after hospital discharge, we categorized the study population into “Premature DC group” and “Continuous group”. Then we compared the demographic and clinical characteristics between the two groups. Survival analysis. Our study endpoint was ACS-related rehospitalization. We used time-dependent Cox’s proportional hazard model to evaluate the hazard ratio (HR) between clopidogrel continuers and discontinuers for ACS-related rehospitalization. Besides, we performed similar analyses in the subgroup of DES-treated patients. Results: A total of 975 patients were included in this study. The mean duration of follow-up was 27 months. Prescription analysis. The mean clopidogrel-covered days were 259.38 days with an interquartile range of 145.25 to 373.51 days. There were 57.4 % of patients received duration of clopidogrel beyond 9 months, the median number of clopidogrel-covered days was 364 days, and 48.6 % of them ever had self-pay clopidogrel. Descriptive analysis. Patients with ≧12 months duration of clopidogrel therapy were more likely to present with MI at the first ACS hospitalization, have hypertension, multivessel disease, DES implantation, lesions located at right coronary artery (RCA), longer stent length and smaller stent diameter. Patients with≧15 months duration were older and more likely to have multivessel disease, ostium lesion, DES implantation, lesion located at LM, ≧2 stents implantation and longer stent length. Survival analysis. The clopidogrel therapy ≧9 months reduced risk for ACS-rehospitalization (adjusted hazard ratio [HR]=0.69; 95 % CI=0.48-1.00; p=0.05). Those who received clopidogrel for ≧12 months also had a lower ACS-rehospitalization rate (adjusted HR=0.59; 95 % CI=0.36-0.95; p=0.03). However, clopidogrel therapy ≧15 months did not show a significant benefit (adjusted HR=0.57; 95 % CI=0.29-1.13; p=0.11). In DES subgroup analysis, those who received clopidogrel for ≧12 months also had a lower ACS-rehospitalization rate (adjusted HR=0.52; 95 % CI=0.29-0.92; p=0.02). However, therapy duration ≧9 months was not associated with lower incidence of ACS-rehospitalization (adjusted HR=0.68; 95 % CI=0.44-1.06; p=0.09). This meant that clopidogrel therapy up to 9 months was not sufficient to those with DES, and it showed the benefit only if duration of clopidogrel use up to 12 months. Besides, clopidogrel therapy≧15 months did not reduce risk for ACS-rehospitalization (adjusted HR=0.76; 95 % CI=0.37-1.56; p=0.45). Conclusion: 12 months of clopidogrel therapy may be ideal for all patients with acute coronary syndrome, especially if a DES is implanted. In contrast, clopidogrel therapy up to 9 months covered by NHI showed insufficiency to provide maximum benefit. Therefore, we suggest the reimbursement from NHI to provide the addition of clopidogrel to aspirin up to 12 months. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T04:51:08Z (GMT). No. of bitstreams: 1 ntu-100-R98451003-1.pdf: 7302767 bytes, checksum: 78bfb2b128159aec56660cc5655a7688 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 謝辭 i
中文摘要 i Abstract iii 目錄 v 表目錄 ix 圖目錄 xii 縮寫表 1 第 1 章 前言 2 第 2 章 文獻探討 4 第一節 急性冠心症 4 2.1.1簡介 4 2.1.2 急性冠心症的流行病學 4 2.1.3 急性冠心症之病因學 5 第二節 急性冠心症的表現與急性期處置 6 2.2.1 ST波上升型ACS (STE ACS) 6 2.2.2非ST波上升型ACS (NSTE ACS) 7 第三節 急性冠心症病人之藥物治療 10 2.3.1 Aspirin於急性冠心症之使用 10 2.3.2 Clopidogrel於急性冠心症之使用 11 2.3.2.1 Clopidogrel之介紹 11 2.3.2.2 Clopidogrel於急性冠心症之治療 11 2.3.3 Clopidogrel與aspirin併用(雙重抗血小板療法)於急性冠心症之使用 12 2.3.3.1臨床試驗 12 2.3.3.2美國心臟醫學會及心臟協會(ACC/AHA)治療指引 16 2.3.3.3 Clopidogrel於台灣健保給付規定 17 第四節 雙重抗血小板療法於塗藥支架病人之考量 21 2.4.1塗藥支架的介紹 21 2.4.2塗藥支架與晚期支架栓塞的相關性 21 2.4.3植入塗藥支架病人發生晚期支架栓塞的危險因子 23 2.4.4雙重抗血小板藥物療程時間與塗藥支架栓塞或心血管事件相關性研究 24 第 3 章 研究目的 30 第 4 章 研究方法 31 第一節 研究材料 31 第二節 研究架構、研究族群、研究分組建立 32 4.2.1 研究架構 32 4.2.2 研究族群納入與排除條件 34 4.2.3 研究期間定義 37 4.2.4 研究終點定義 37 4.2.5 研究分組定義 38 4.2.6 研究資料收集 40 第三節 統計分析 44 4.3.1 研究族群之描述性統計分析 44 4.3.2 研究終點事件存活分析 45 4.3.3 統計軟體 45 第 5 章 研究結果 46 第一節 研究族群的建立與處方分析 46 5.1.1新住院診斷為急性冠心症(ACS)且接受經皮冠狀動脈介入術病人群 46 5.1.2接受經皮冠狀動脈介入術之ACS病人群於術後使用aspirin與clopidogrel處方情形 47 5.1.3最終研究族群:新住院診斷為急性冠心症並且接受經皮冠狀動脈介入術的clopidogrel使用病人 49 第二節 九個月療程分析 52 5.2.1九個月療程分析之研究族群 52 5.2.2背景資料分析 52 5.2.2.1基本資料 52 5.2.2.2急性冠心症相關資料 54 5.2.2.3共病症與用藥資料 56 5.2.3 研究終點事件之基本分析 58 5.2.4 再次發生ACS住院事件之存活分析 60 5.2.5 植入塗藥支架病人次群體之研究終點事件存活分析 65 第三節 十二個月療程分析 70 5.3.1十二個月療程分析之研究族群 70 5.3.2背景資料分析 70 5.3.2.1基本資料 70 5.3.2.2急性冠心症相關資料 72 5.3.2.3共病症與用藥資料 74 5.3.3 研究終點事件之基本分析 76 5.3.4 再次發生ACS住院事件之存活分析 78 5.3.5 植入塗藥支架病人次群體之研究終點事件存活分析 83 第四節 十五個月療程分析 88 5.4.1十五個月療程分析之研究族群 88 5.4.2背景資料分析 89 5.4.2.1基本資料 89 5.4.2.2急性冠心症相關資料 90 5.4.2.3共病症與用藥資料 90 5.4.3研究終點事件基本分析 93 5.4.4再次發生ACS住院事件之存活分析 94 5.4.5植入塗藥支架病人次群體之研究終點事件存活分析 99 第 6 章 討論 104 第一節 研究族群之處方分析 104 6.1.1 研究族群於術後使用aspirin與clopidogrel處方情形 104 6.1.2 研究族群之clopidogrel處方型態 106 第二節 研究族群之背景資料分析 107 6.2.1 整體研究族群之背景資料分析 107 6.2.2 Premature DC組與Continuous組之間的背景資料差異 109 第三節 研究族群之追蹤時間及研究終點事件基本分析 113 第四節 存活分析 114 6.4.1 九個月療程分析 114 6.4.2 十二個月療程分析 115 6.4.3 十五個月療程分析 117 6.4.4 塗藥支架病人之療程分析 119 6.4.5 其他顯著影響研究終點事件的因素 121 6.4.6 九個月、十二個月、十五的月療程分析研究族群之比較 122 6.4.7 研究終點事件之驗證 125 第五節 研究限制與優點 127 6.5.1 研究限制 127 6.5.2 研究優點與特色 127 第 7 章 結論 128 參考文獻 129 | |
dc.language.iso | zh-TW | |
dc.title | 急性冠心症病人使用雙重抗血小板藥物療程時間與再發生心血管事件之風險分析 | zh_TW |
dc.title | Duration of Dual Antiplatelet Therapy and Recurrent Cardiovascular Events for Patients with Acute Coronary Syndrome | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 蕭斐元(Fei-Yuan Sharon Hsiao) | |
dc.contributor.oralexamcommittee | 李啟明(Chii-Ming Lee),林美淑 | |
dc.subject.keyword | clopidogrel,急性冠心症,雙重抗血小板藥物,clopidogrel療程,塗藥支架, | zh_TW |
dc.subject.keyword | clopidogrel,acute coronary syndrome,dual antiplatelet therapy,duration of clopidogrel,drug-eluting stents, | en |
dc.relation.page | 135 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2011-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 7.13 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。